We are proud to announce that our products have been granted a patent by the Italian Patent and Trademark Office (UIBM – Ufficio Italiano Brevetti e Marchi), the national authority responsible for the protection and management of industrial property rights in Italy.
The patented invention relates to a composition containing extracts of Cannabis sativa L. designed for use in the treatment of inflammatory bowel disease (IBD) and/or in the prevention of intestinal conditions linked to acute or chronic inflammation, with or without associated dysbiosis.
A composition comprising a blend of at least two standardized extracts in their active components coming from a stable variety of Cannabis sativa L., for use in the treatment of an inflammatory bowel disease and/or in the prevention of bowel diseases correlated to acute, chronic inflammation and dysbiosis. Such standardized extracts comprise the active components cannabigerol and cannabidiol in various mass ratios, with a concentration of THC, CBN and THCV consistently and significantly maintained under 0.2% and therefore well below the thresholds associated with narcotic effects.
This significant achievement follows the publication last October of Linnea’s first investigation on CBG:CBD-rich extracts, carried out in collaboration with University of Milan, that examined the impact of extraction processes on efficacy, the stability of cannabis extracts during digestion, and the synergistic effects of CBG and CBD in bowel inflammation and microbiota preservation.
Such recognition marks an important milestone in our research journey and strengthens our commitment to developing innovative solutions that support gastrointestinal health and wellbeing.
We look forward to continuing our work in advancing science-based approaches that can make a meaningful difference.
Official Archive → https://www.uibm.gov.it/bancadati/
